Hengrui Pharma(SH:600276) GLP1减重宝典·2026-01-05 15:57Core Viewpoint - The article highlights the significant progress of the domestically developed weight-loss drug Ribupatide (HRS9531) by Heng Rui Medicine, marking its official entry into the public domain as a dual receptor agonist targeting GLP-1 and GIP, aimed at overweight and obese populations, as well as related comorbidities and type 2 diabetes [5]. Group 1: Drug Development and Mechanism - Ribupatide acts on both GLP-1 and GIP receptors, addressing the appetite suppression and metabolic efficiency while mitigating gastrointestinal side effects associated with GLP-1 alone [6]. - The introduction of GIP enhances the therapeutic effect, allowing for significant weight loss at lower doses and shorter treatment durations, thus improving both efficacy and safety [6]. Group 2: Clinical Data and Efficacy - Early studies show that a starting dose of 1mg for two weeks resulted in an average weight loss of approximately 5 pounds, indicating a rapid metabolic response [7]. - In Phase III clinical trials, patients receiving a weekly injection of 6mg for 48 weeks experienced an average weight loss of 19.2%, equivalent to about 35 pounds, with a waist circumference reduction of 14.4 cm, placing it among the top tier of global GLP-1 weight-loss drugs [7]. - Higher doses (8mg) demonstrated even greater potential, with a weight loss of 23.6% over 36 weeks, showing no significant plateau effect, suggesting continued weight loss potential [7]. Group 3: Safety Profile - Ribupatide has a low rate of permanent discontinuation due to adverse events, at only 0.9%, indicating a robust safety profile that supports its future widespread application in real-world settings [7].